- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04350333
Efficacy of Digital CBT-I Intervention During Pregnancy
26. april 2021 oppdatert av: Valeria Bacaro, University of Rome G. Marconi
Efficacy of Digital Cognitive Behavioral Therapy for Insomnia (CBT-I) Intervention During Pregnancy in Prevention of Post-partum Depression: a Randomized Clinical Trial
This randomized controlled trial aims to evaluate the efficacy of Cognitive Behavioral Therapy for Insomnia in pregnant women.
Particularly, this study aim to explore the effect of this intervention in ameliorating insomnia symptoms and in preventing post-partum depression disorder.
The experimental intervention is a digital CBT-I and the control intervention group is an assertive communication training.
Both interventions include a screening phase and will be delivered in a digital way and will be composed of 5 sessions.
Furthermore, both interventions protocol include a baseline, half time and follow up assessments.
Studieoversikt
Status
Har ikke rekruttert ennå
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Forventet)
114
Fase
- Ikke aktuelt
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
19 år til 40 år (Voksen)
Tar imot friske frivillige
Ja
Kjønn som er kvalifisert for studier
Hunn
Beskrivelse
Inclusion Criteria:
- Healthy pregnancy
- Women that not consume nicotine or alcool
- BMI < 30
- Women who complains of insomnia or bad sleep quality
Exclusion Criteria:
- BMI> 30
- Complicated pregnancy
- Women who consume nicotine or alcool
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: CBT-I group
Five sessions composed of: psychoeducation on sleep change during pregnancy and postpartum; sleep hygiene principles; stimulus control technique, sleep restriction technique (f this technique will be too difficult for the participants to be apply, a replacement and less disabling technique will be applied: sleep compression); psychoeducation on the child's sleep at birth and on the change in the sleep-wake cycle in the early stages of the child's life; cognitive control technique; cognitive reconstruction technique and de-catastrophization; relapses prevention.
|
Strategies and techniques of Cognitive behavioral therapy for insomnia adapted for pregnant women: stimulus control; sleep hygiene; sleep restriction; cognitive control etc.
|
|
Aktiv komparator: Assertive communication training
Five sessions composed of: psychoeducation and explanation of the importance of emotional and cognitive factors for good sleep.
Psychoeducation about the concept of assertiveness, explanation of the passive, aggressive and assertive style; explanation and exercises regarding self-esteem and positive self-image; explanation of the development of sleep of the child in the first years of life; explanation and exercises on the phase of the management of feedback and requests; conflict management; relapses prevention.
|
Intervention based on improving assertive communication and regulating emotions.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Depression
Tidsramme: Follow up: 2 weeks post partum
|
Depression symptomatology (Edinburgh Postnatal Depression Scale - EPDS).
Scoring: < 8: depression not likely; 9-11: depression possible; 12-13:Fairly high possibility of depression; > 14 probable depression
|
Follow up: 2 weeks post partum
|
|
Depression
Tidsramme: Follow up: 3 months post partum
|
Depression symptomatology (Edinburgh Postnatal Depression Scale - EPDS).
Scoring: < 8: depression not likely; 9-11: depression possible; 12-13:Fairly high possibility of depression; > 14 probable depression
|
Follow up: 3 months post partum
|
|
Depression
Tidsramme: Follow up: 6 months post partum
|
Depression symptomatology (Edinburgh Postnatal Depression Scale - EPDS).
Scoring: < 8: depression not likely; 9-11: depression possible; 12-13:Fairly high possibility of depression; > 14 probable depression
|
Follow up: 6 months post partum
|
|
Anxiety
Tidsramme: Follow up: 2 weeks post partum
|
Anxiety symptomatology (State-trait anxiety inventory - STAI-Y).
Higher scores mean a worse outcome.
|
Follow up: 2 weeks post partum
|
|
Anxiety
Tidsramme: Follow up: 3 months post partum
|
Anxiety symptomatology (State-trait anxiety inventory - STAI-Y).
Higher scores mean a worse outcome.
|
Follow up: 3 months post partum
|
|
Anxiety
Tidsramme: Follow up: 6 months post partum
|
Anxiety symptomatology (State-trait anxiety inventory - STAI-Y).
Higher scores mean a worse outcome.
|
Follow up: 6 months post partum
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Sleep pattern (sleep onset latency; total sleep time; wake after sleep onset; sleep efficiency)
Tidsramme: Post intervention: after 5 weeks from the start of intervention
|
sleep pattern derived from sleep diaries
|
Post intervention: after 5 weeks from the start of intervention
|
|
insomnia symptoms
Tidsramme: Post intervention: after 5 weeks from the start of intervention
|
Insomnia severity index scores (ISI).
Scoring: 0-7 = No clinically significant insomnia 8-14 = Subthreshold insomnia 15-21 = Clinical insomnia (moderate severity) 22-28 = Clinical insomnia (severe)
|
Post intervention: after 5 weeks from the start of intervention
|
|
Emotion regulation
Tidsramme: Post intervention: after 5 weeks from the start of intervention
|
Emotion Regulation Questionnaire (ERQ) - Higher scores mean better outcome.
|
Post intervention: after 5 weeks from the start of intervention
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Forventet)
1. mai 2021
Primær fullføring (Forventet)
31. desember 2021
Studiet fullført (Forventet)
31. desember 2021
Datoer for studieregistrering
Først innsendt
6. april 2020
Først innsendt som oppfylte QC-kriteriene
14. april 2020
Først lagt ut (Faktiske)
17. april 2020
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
27. april 2021
Siste oppdatering sendt inn som oppfylte QC-kriteriene
26. april 2021
Sist bekreftet
1. april 2021
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- UMarconi
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
UBESLUTTE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .